The Europe and Middle East & Africa (EMEA) point-of-care diagnostics market size was USD 7.73 Billion in 2022 and is likely to reach USD 14.21 Billion by 2031, expanding at a CAGR of 7% during the forecast period, 2023–2031. The growth of the market is attributed to the increasing number of global population along with high prevalence rates of recurring diseases.
The point-of-care diagnostics include the identification of various abstracts related to applied trials, observations, and simulations for the treatment required. This test evaluation report and a summary of the study is usually forwarded to the concerned clinics, which take the major decision to proper treatment for the disease of patients.
Over the years, various kinds of point-of-care-tests were developed to study different anatomies of the body, be it internal or external. For instance, after the introduction of urine test strips, in which the patient’s urine strip is examined on a separate apparatus for the detection of drugs or toxic, the test result of portable ultrasonography is found better improvement and showing accurate readings in limited time.
The idea behind the launch of point-of-care tests was to conduct tests immediately, which are convenient to the patients. Using this diagnostic data, it is likely that the physician and the healthcare team can work efficiently in deciding the treatment for patients. According to the WHO survey statistics in 2020, the point-of-care testing devices are adopted by one-in-five patients, which is expected to increase to one-in-three by 2025.
The COVID-19 pandemic has accelerated the growth of the market globally, particularly the EMEA primary care point-of-care diagnostics market. Point-of-care testing is increasingly adopted in various hospitals as it is considered to be one of the perfect tools and analysis for this pandemic situation. A large amount of funding invested by hospital bodies to start research of the point-of-care-tests, fueling the growth of the EMEA point-of-care diagnostics market.
Market Trends, Drivers, Restraints, and Opportunities
-
Increasing the range of applications of the point-of-care diagnostics testing along with the decentralization of healthcare facilities for providing remote access are projected to boost the market growth during the forecast period.
-
Rapid advancement of point-of-care testing devices and ease of use as well as portability are major factors driving the market expansion in the coming years.
-
Requirement of special environment to store devices and equipment used in point-of-care testing leads to high maintenance cost, thereby, acting as a key factor hindering the point-of-care diagnostics market growth in the EMEA region.
-
Lack of reliability in the results obtained by the point-of-care testing devices present as a major factor to restrict the market growth. The tests conducted by these devices are meant for preliminary reports alone and not for final analysis.
-
R&D investment and technological advancement are expected to offer significant opportunities for the market players. Researchers and scientists have now discovered innovative technology such as the Picture Archiving and Communication Systems or the PACS and the Electronic Medical Records or the EMR as IT support systems.
Scope of EMEA Point-of-care Diagnostics Market Report
The report on the EMEA point-of-care diagnostics market size includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
EMEA Point-of-care Diagnostic Market - EMEA Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Products (Glucose Testing [Over the Counter and Prescribed], Cardiac Markers, Fertility, Blood Gas & Electrolytes, Decentralized Clinical Chemistry, Infectious Disease Testing, Coagulation [Over the Counter and Prescribed], Primary Care Systems, Hematology, Urinalysis, Drug Abuse Testing, and Others), and End-users (Hospitals, Clinics, Laboratories, Assisted Living Healthcare Facilities, Home Healthcare Facilities, and Others)
|
|
Regional Scope
|
Europe and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Beckman Coulter Inc; Roche Diagnostics; Siemens Healthcare; Abbott Laboratories; Danaher Corporation; Becton, Dickinson and Company; bioMerieux SA; Abaxis Inc; Alere Inc; Qiagen NV; Spectral Diagnostic Inc; HemoCue AB; Nova Biomedical; and Quidel Corporation
|
EMEA Point-of-care Diagnostics Market Segment Insights
Glucose testing segment is projected to represent a large market share
Based on the products, the EMEA point-of-care diagnostics market is segmented into glucose testing, cardiac markers, fertility, blood gas & electrolytes, decentralized clinical chemistry, infectious disease testing, coagulation, primary care systems, hematology, urinalysis, drug abuse testing, and others. Glucose testing and coagulation are further bifurcated into the over the counter or the OTC and the prescribed.
The glucose testing segment is expected to constitute a major share of the market during the forecast period, 2021-2028 owing to the increasing adoption of various self-testing glucose devices. They play an essential role in terms of regulating glycemic levels on a regular basis. This is also now anticipated for providing positive health outcomes including diabetes.
Meanwhile, the cardiac markers segment is anticipated to exhibit a robust growth with a CAGR of more than 8.1% during the forecast period. This segment growth can be attributed to the escalating number of cardiac diseases because of the sedentary lifestyle of people, along with the advancement of cardiac markers equipment with boosted accuracy and high precision.
Clinics is expecting to grow at a significant pace
On the basis of end-users, the EMEA point-of-care diagnostics market is divided into hospitals, clinics, laboratories, assisted living healthcare facilities, home healthcare facilities, and others. The clinics segment is expected to constitute a major market share accounting for more than 38% of the total market revenue during the forecast period.
The segment growth can be attributed to the high volumes of procedures related with the establishments of point-of-care diagnostics devices along with the increase in rapid clinics using only specific point-of-care diagnostic tests.
On the other hand, the home healthcare facilities segment is expected to register a substantial CAGR during the forecast years owing to the increasing need of home healthcare setting for various diseases treatment. Moreover, the rising demand for continuous monitoring for the treatment of diseases and rising awareness of the patients, especially in the EMEA region present key drivers for the segment growth.
Europe is anticipated to dominate the market
On the basis of regions, the EMEA point-of-care diagnostics market is bifurcated into Europe and Middle East & Africa. Europe is expecting to expand at an impressive CAGR during the forecast period, 2021-2028 owing to the introduction of various government contracts on the healthcare infrastructure development that are contributing towards the rising demand for the point-of-care diagnostics equipment.
On the other hand, the market in Middle East & Africa is projected to hold a key market share in the coming years. In the regions, countries such as Saudi Arabia and the United Arab Emirates are expected to register robust CAGR during the forecast period due to the levy of easy market access. The breakout of the COVID-19 pandemic is also a major factor for this given regional growth.
Segments
The EMEA point-of-care diagnostics market size has been segmented in terms of
Products
- Glucose Testing
- Over the Counter
- Prescribed
- Cardiac Markers
- Fertility
- Blood Gas & Electrolytes
- Decentralized Clinical Chemistry
- Infectious Disease Testing
- Coagulation
- Over the Counter
- Prescribed
- Primary Care Systems
- Hematology
- Urinalysis
- Drug Abuse Testing
- Others
End-users
- Hospitals
- Clinics
- Laboratories
- Assisted Living Healthcare Facilities
- Home Healthcare Facilities
- Others
Regions
- Europe
- Middle East & Africa
Key Players
- Beckman Coulter Inc.
- Roche Diagnostics
- Siemens Healthcare
- Abbott Laboratories
- Danaher Corporation
- Becton, Dickinson and Company
- bioMerieux SA
- Abaxis Inc
- Alere Inc
- Qiagen NV
- Spectral Diagnostic Inc
- HemoCue AB
- Nova Biomedical
- Quidel Corporation
Competitive Landscape
Major players competing in the EMEA point-of-care diagnostics market are Beckman Coulter Inc; Roche Diagnostics; Siemens Healthcare; Abbott Laboratories; Danaher Corporation; Becton, Dickinson and Company; bioMerieux SA; Abaxis Inc; Alere Inc; Qiagen NV; Spectral Diagnostic Inc; HemoCue AB; Nova Biomedical; and Quidel Corporation.
These market players are involved in several business strategies such as mergers, acquisitions partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For instance, Roche Diagnostics bought 12% of the IQuum stake back in 2014 and now acquired the entire company in 2019. The development was aimed to strengthen the company’s point-of-care diagnostics segment in the molecular diagnostics.
Players are simultaneously looking to produce innovative products in order to get a competitive edge in the market. For instance, Roche Diagnostics launched the CoaguChek Pro IV point-of-care system, which could immediately diagnose the presence of the COVID-19 in the testing and check the coagulation level of the patient’s blood for reporting analysis.
Request For Customization
Enquiry Before Buying
Speak With Analyst
